Nipro to Shift Domestic Depreciation Method to Align With Overseas Operations

Nipro ( (JP:8086) ) has shared an update.

Nipro announced that it will change the depreciation method for property, plant, and equipment at the parent company and domestic consolidated subsidiaries from the declining-balance method to the straight-line method. The shift reflects that overseas operations now account for more than half of its business and is aimed at aligning accounting practices with overseas subsidiaries that already use straight-line depreciation.

The new method will take effect from the fiscal year ending March 31, 2027, and is expected to affect reported earnings once implemented. Nipro said it will release a consolidated earnings forecast for that fiscal year, incorporating the impact of the depreciation change, once the outlook is finalized, signaling potential implications for profitability metrics and comparability of future financial results for investors.

The most recent analyst rating on (JP:8086) stock is a Hold with a Yen1593.00 price target. To see the full list of analyst forecasts on Nipro stock, see the JP:8086 Stock Forecast page.

More about Nipro

Nipro Corporation is a Japan-based medical device and pharmaceutical company listed on the Prime Market under securities code 8086. The group develops, manufactures, and sells products such as dialysis-related equipment, injection and infusion systems, and other medical supplies, with a growing share of its operations and earnings coming from overseas subsidiaries and markets.

Average Trading Volume: 629,532

Technical Sentiment Signal: Buy

Current Market Cap: Yen240.9B

For detailed information about 8086 stock, go to TipRanks’ Stock Analysis page.